SAK, a new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis upon RNAi silencing

Neoplasia

Volumn 7, Issue 4, 2005, Pages 312-323

  Li, Jun ^a,b   Tan, Mingjia ^a   Li, Ling ^c   Pamarthy, Deepika ^a   Lawrence, Theodore S ^a   Sun, Yi ^a,d  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b Experimental Station   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; p53; Polo like kinase; Repression; RNAi silencing; Transcription

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; LUCIFERASE; POLO LIKE KINASE; PROTEIN P53; PROTEIN SAK; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR SP1; TRICHOSTATIN A; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING SITE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; GENE DELETION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SEQUENCE; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; TEMPERATURE SENSITIVITY; TRANSCRIPTION REGULATION; TUMOR CELL; TUMOR MODEL;

EID: 18644372124     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1593/neo.04325     Document Type: Article

References (65)

1. Giaccia AJ and Kastan MB (1998). The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 12, 2973-2983.
2. Levine AJ (1997). p53, the cellular gatekeeper for growth and division. Cell 88, 323-331.
3. Ko LJ and Prives C (1996). p53: puzzle and paradigm. Genes Dev 10, 1054-1072.
4. Chan TA, Hermeking H, Lengauer C, Kinzler KW, and Vogelstein B (1999). 14-3-3s is required to prevent mitotic catastrophe after DNA damage. Nature 401, 616-620.
5. el Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, and Vogelstein B (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
6. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, and Vogelstein B (1997). 14-3-3 Sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1, 3-11.
7. Tan M, Wang Y, Guan K, and Sun Y (2000). PTGFb, a type b transforming growth factor (TGFb) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGFb signaling pathway. Proc Natl Acad Sci USA 97, 109-114.
8. Fei P, Bernhard EJ, and El-Deiry WS (2002). Tissue-specific induction of p53 targets in vivo. Cancer Res 62, 7316-7327.
9. Vogelstein B, Lane D, and Levine AJ (2000). Surfing the p53 network. Nature 408, 307-310.
10. Miyashita T and Reed JC (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293-299.
11. Nakano K and Vousden KH (2001). PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7, 683-694.
12. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, and Tanaka N (2000). Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288, 1053-1058.
13. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, et al. (2000). p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102, 849-862.
14. Polyak K, Xia Y, Zweier JL, Kinzler KW, and Vogelstein B (1997). A model for p53-induced apoptosis [see comments]. Nature 389, 300-305.
15. Yu J, Zhang L, Hwang PM, Kinzler KW, and Vogelstein B (2001). PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7, 673-682.
16. Lin Y, Ma W, and Benchimol S (2000). Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nat Genet 26, 122-127.
17. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, et al. (1995). Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15, 3032-3040.
18. Wu GS, Burns TF, McDonald III, ER, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, et al. (1997). KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene [letter]. Nat Genet 17, 141-143.
19. Hoffman WH, Biade S, Zilfou JT, Chen J, and Murphy M (2002). Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 277, 3247-3257.
20. Werner H, Karnieli E, Rauscher FJ, and LeRoith D (1996). Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci USA 93, 8318-8323.
21. Wu Y, Mehew JW, Heckman CA, Arcinas M, and Boxer LM (2001). Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 20, 240-251.
22. Johnson RA, Ince TA, and Scotto KW (2001). Transcriptional repression by p53 through direct binding to a novel DNA element. J Biol Chem 276, 27716-27720.
23. Li J, Jiang P, Robinson M, Lawrence TS, and Sun Y (2003). AMPK-beta1 subunit is a p53-independent stress responsive protein that inhibits tumor cell growth upon forced expression. Carcinogenesis 24, 827-834.
24. Fode C, Motro B, Yousefi S, Heffernan M, and Dennis JW (1994). Sak, a murine protein-serine/threonine kinase that is related to the Drosophila polo kinase and involved in cell proliferation. Proc Natl Acad Sci USA 91, 6388-6392.
25. Fode C, Binkert C, and Dennis JW (1996). Constitutive expression of murine Sak-a suppresses cell growth and induces multinucleation. Mol Cell Biol 16, 4665-4672.
26. Hudson JW, Kozarova A, Cheung P, Macmillan JC, Swallow CJ, Cross JC, and Dennis JW (2001). Late mitotic failure in mice lacking Sak, a polo-like kinase. Curr Biol 11, 441-446.
27. Karn T, Holtrich U, Wolf G, Hock B, Strebhardt K, and Rubsamen-Waicmann H (1997). Human SAK related to the PLK/polo family of cell cycle kinases shows high mRNA expression in testis. Oncol Rep 4, 505-510.
28. Pochampally R, Fodera B, Chen L, Lu W, and Chen J (1999). Activation of an MDM2-specific caspase by p53 in the absence of apoptosis. J Biol Chem 274, 15271-15277.
29. Wang Y, Rea T, Bian J, Gray S, and Sun Y (1999). Identification of the genes responsive to etoposide-induced apoptosis: application of DNA chip technology. FEBS Lett 445, 269-273.
30. Sun Y, Pommier Y, and Colburn NH (1992). Acquisition of a growth-inhibitory response to phorbol ester involves DNA damage. Cancer Res 52, 1907-1915.
31. el Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, and Vogelstein B (1992). Definition of a consensus binding site for p53. Nat Genet 1, 45-49.
32. Bian J, Jacobs C, Wang Y, and Sun Y (1996). Characterization of a putative p53 binding site in the promoter of the mouse tissue inhibitor of metalloproteinases-3 (TIMP-3) gene: TIMP-3 is not a p53 target gene. Carcinogenesis 17, 2559-2562.
33. Bian J and Sun Y (1997). p53CP, a putative p53 competing protein that specifically binds to the consensus p53 DNA binding sites: a third member of the p53 family? Proc Natl Acad Sci USA 94, 14753-14758.
34. Kaeser MD and Iggo RD (2002). From the cover: Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci USA 99, 95-100.
35. Zeng SY, Dai M-S, Keller DM, and Lu H (2002). SSRP1 functions as a co-activator of the transcriptional activator p63. EMBO J 21, 5487-5497.
36. Yamashita Y, Kajigaya S, Yoshida K, Ueno S, Ota J, Ohmine K, Ueda M, Miyazato A, Ohya K, Kitamura T, et al. (2001). Sak serine-threonine kinase acts as an effector of Tec tyrosine kinase. J Biol Chem 276, 39012-39020.
37. Huang Y, Tan M, Gosink M, Wang KK, and Sun Y (2002). Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis. Cancer Res 62, 2913-2922.
38. Sun Y, Bian J, Wang Y, and Jacobs C (1997). Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound. Oncogene 14, 385-393.
39. Robinson M, Jiang P, Cui J, Li J, Wang Y, Swaroop M, Madore S, Lawrence TS, and Sun Y (2003). Global Genechip profiling to identify genes responsive to p53-induced growth arrest and apoptosis in human lung carcinoma cells. Cancer Biol Ther 2, 406-415.
40. Scheffner M, Huibregtse JM, Vierstra RD, and Howley PM (1993). The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75, 495-505.
41. Hudson JW, Chen L, Fode C, Binkert C, and Dennis JW (2000). Sak kinase gene structure and transcriptional regulation. Gene 241, 65-73.
42. el Deiry WS (1998). Regulation of p53 downstream genes. Semin Cancer Biol 8, 345-357.
43. Farmer G, Friedlander P, Colgan J, Manley JL, and Prives C (1996). Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein. Nucleic Acids Res 24, 4281-4288.
44. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, and George DL (1999). Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 13, 2490-2501.
45. Gurova KV, Roklin OW, Krivokrysenko VI, Chumakov PM, Cohen MB, Feinstein E, and Gudkov AV (2002). Expression of prostate specific antigen (PSA) is negatively regulated by p53. Oncogene 21, 153-157.
46. Bian J and Sun Y (1997). Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. Mol Cell Biol 17, 6330-6338.
47. Lee KC, Crowe AJ, and Barton MC (1999). p53-mediated repression of alpha-fetoprotein gene expression by specific DNA binding. Mol Cell Biol 19, 1279-1288.
48. Li B and Lee MY (2001). Transcriptional regulation of the human DNA polymerase delta catalytic subunit gene POLD1 by p53 tumor suppressor and Sp1. J Biol Chem 276, 29729-29739.
49. Manni I, Mazzaro G, Gurtner A, Mantovani R, Haugwitz U, Krause K, Engeland K, Sacchi A, Soddu S, and Piaggio G (2001). NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest. J Biol Chem 276, 5570-5576.
50. Yun J, Chae HD, Choy HE, Chung J, Yoo HS, Han MH, and Shin DY (1999). p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J Biol Chem 274, 29677-29682.
51. Modugno M, Tagliabue E, Ardini E, Berno V, Galmozzi E, De Bortoli M, Castronovo V, and Menard S (2002). p53-dependent downregulation of metastasis-associated laminin receptor. Oncogene 21, 7478-7487.
52. Sun Y, Sun Y, Wenger L, Rutter JL, Brinckerhoff CE, and Cheung HS (1999). p53 down-regulates human matrix metalloproteinase-1 (Collagenase-1) gene expression. J Biol Chem 274, 11535-11540.
53. Kubicka S, Kuhnel F, Zender L, Rudolph KL, Plumpe J, Manns M, and Trautwein C (1999). p53 represses CAAT enhancer-binding protein (C/EBP)-dependent transcription of the albumin gene. A molecular mechanism involved in viral liver infection with implications for hepato-carcinogenesis. J Biol Chem 274, 32137-32144.
54. Zhang X, Grand RJ, McCabe CJ, Franklyn JA, Gallimore PH, and Turnell AS (2002). Transcriptional regulation of the human glycoprotein hormone common alpha subunit gene by cAMP-response-element-binding protein (CREB)-binding protein (CBP)/p300 and p53. Biochem J 368, 191-201.
55. Dai W, Wang Q, and Traganos F (2002). Polo-like kinases and centrosome regulation. Oncogene 21, 6195-6200.
56. Donaldson MM, Tavares AA, Hagan IM, Nigg EA, and Glover DM (2001). The mitotic roles of Polo-like kinase. J Cell Sci 114, 2357-2358.
57. Nigg EA (2001). Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2, 21-32.
58. Leung GC, Hudson JW, Kozarova A, Davidson A, Dennis JW, and Sicheri F (2002). The Sak polo-box comprises a structural domain sufficient for mitotic subcellular localization. Nat Struct Biol 9, 719-724.
59. Yuan J, Kramer A, Eckerdt F, Kaufmann M, and Strebhardt K (2002). Efficient internalization of the polo-box of polo-like kinase 1 fused to an Antennapedia peptide results in inhibition of cancer cell proliferation. Cancer Res 62, 4186-4190.
60. Spankuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmuller M, von Minckwitz G, Kaufmann M, and Strebhardt K (2002). Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 21, 3162-3171.
61. Masuda Y, Nishida A, Hori K, Hirabayashi T, Kajimoto S, Nakajo S, Kondo T, Asaka M, and Nakaya K (2003). Beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1). Oncogene 22, 1012-1023.
62. Wang Q, Xie S, Chen J, Fukasawa K, Naik U, Traganos F, Darzynkiewicz Z, Jhanwar-Uniyal M, and Dai W (2002). Cell cycle arrest and apoptosis induced by human Polo-like kinase 3 is mediated through perturbation of microtubule integrity. Mol Cell Biol 22, 3450-3459.
63. Burns TF, Fei P, Scata KA, Dicker DT, and El-Deiry WS (2003). Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol 23, 5556-5571.
64. Kho PS, Wang Z, Zhuang L, Li Y, Chew JL, Ng HH, Liu ET, and Yu Q (2004). p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem 279, 21183-21192.
65. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S, Fukuzawa M, and Nakagawara A (2004). Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 279, 25549-25561.